FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387600029> ?p ?o ?g. }

• W4387600029 abstract "People with cystic fibrosis (pwCF) commonly test positive for the pathogenic fungus Aspergillus fumigatus, which is associated with a decline in lung function. Trikafta is a recently approved therapy for pwCF that improves quantity and function of the CFTR protein; however, it is not known how Trikafta affects microbial communities in the lung. Therefore, the aim of this study was to determine whether Trikafta directly affects A. fumigatus growth and biology. While Trikafta did not impact the viability of A. fumigatus conidia, treatment of A. fumigatus biofilms with Trikafta reduced overall biofilm biomass. This finding was associated with increased membrane permeability, decreased viability, and reduced metabolic activity following long-term treatment of biofilms. Trikafta-induced membrane permeability, and biomass reduction was partially blocked with the calcium channel inhibitor verapamil and fully blocked by the mammalian CFTR inhibitor GlyH-101. Trikafta-induced biomass reduction and metabolic activity was shown to be regulated by the high-osmolarity glycerol pathway gene sakA. Trikafta treatment also induced resistance to the cell wall stressor calcofluor white, susceptibility to the anti-fungal drug caspofungin, and decreased inflammatory responses from murine bone marrow cells. Collectively, these results reveal that Trikafta affects infection-relevant A. fumigatus biology and host-microbial interactions. IMPORTANCE PwCF commonly test positive for pathogenic fungi, and more than 90% of the cystic fibrosis patient population is approved for the modulator treatment, Trikafta. Therefore, it is critical to understand how fungal communities, specifically A. fumigatus, respond to Trikafta exposure. Therefore, we sought to determine whether Trikafta impacted the biology of A. fumigatus biofilms. Our data demonstrate that Trikafta reduces biomass in several laboratory strains as well as clinical strains isolated from the expectorated sputum of pwCF. Furthermore, Trikafta reduces fungal viability and the capacity of biofilms to recover following treatment. Of particular importance, Trikafta affects how A. fumigatus biofilms respond to cell wall stressors, suggesting that Trikafta modulates components of the cell wall. Since the cell wall directly affects how a host immune system will respond to and effectively neutralize pathogens, our work, demonstrating that Trikafta impacts the A. fumigatus cell wall, is potentially highly relevant to fungal-induced disease pathogenesis." @default.
• W4387600029 created "2023-10-14" @default.
• W4387600029 creator A5000693245 @default.
• W4387600029 creator A5038725561 @default.
• W4387600029 creator A5044428342 @default.
• W4387600029 creator A5050973081 @default.
• W4387600029 creator A5059965188 @default.
• W4387600029 creator A5065643161 @default.
• W4387600029 creator A5074572683 @default.
• W4387600029 creator A5085027597 @default.
• W4387600029 creator A5092222367 @default.
• W4387600029 date "2023-10-13" @default.
• W4387600029 modified "2023-10-14" @default.
• W4387600029 title "The cystic fibrosis treatment Trikafta affects the growth, viability, and cell wall of <i>Aspergillus fumigatus</i> biofilms" @default.
• W4387600029 cites W1609049800 @default.
• W4387600029 cites W1901829041 @default.
• W4387600029 cites W1985371834 @default.
• W4387600029 cites W1991004042 @default.
• W4387600029 cites W1993860856 @default.
• W4387600029 cites W2020291681 @default.
• W4387600029 cites W2022050193 @default.
• W4387600029 cites W2047882185 @default.
• W4387600029 cites W2066649608 @default.
• W4387600029 cites W2077986479 @default.
• W4387600029 cites W2085070189 @default.
• W4387600029 cites W2096209592 @default.
• W4387600029 cites W2098175638 @default.
• W4387600029 cites W2101012696 @default.
• W4387600029 cites W2102731598 @default.
• W4387600029 cites W2104625630 @default.
• W4387600029 cites W2111608627 @default.
• W4387600029 cites W2112048001 @default.
• W4387600029 cites W2112677154 @default.
• W4387600029 cites W2117206304 @default.
• W4387600029 cites W2117555017 @default.
• W4387600029 cites W2120323783 @default.
• W4387600029 cites W2124733101 @default.
• W4387600029 cites W2126924404 @default.
• W4387600029 cites W2126957470 @default.
• W4387600029 cites W2128025573 @default.
• W4387600029 cites W2154125232 @default.
• W4387600029 cites W2164299395 @default.
• W4387600029 cites W2167279371 @default.
• W4387600029 cites W2168124457 @default.
• W4387600029 cites W2201817029 @default.
• W4387600029 cites W2277345660 @default.
• W4387600029 cites W2295632006 @default.
• W4387600029 cites W2550701391 @default.
• W4387600029 cites W2612278270 @default.
• W4387600029 cites W2625378674 @default.
• W4387600029 cites W2805309630 @default.
• W4387600029 cites W2810784262 @default.
• W4387600029 cites W2910494427 @default.
• W4387600029 cites W2953929882 @default.
• W4387600029 cites W2964036952 @default.
• W4387600029 cites W2974067668 @default.
• W4387600029 cites W2982296199 @default.
• W4387600029 cites W2985405196 @default.
• W4387600029 cites W3043910668 @default.
• W4387600029 cites W3081014861 @default.
• W4387600029 cites W3112448433 @default.
• W4387600029 cites W3193345957 @default.
• W4387600029 cites W3197273728 @default.
• W4387600029 cites W4321185914 @default.
• W4387600029 cites W4378951537 @default.
• W4387600029 doi "https://doi.org/10.1128/mbio.01516-23" @default.
• W4387600029 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37830825" @default.
• W4387600029 hasPublicationYear "2023" @default.
• W4387600029 type Work @default.
• W4387600029 citedByCount "0" @default.
• W4387600029 crossrefType "journal-article" @default.
• W4387600029 hasAuthorship W4387600029A5000693245 @default.
• W4387600029 hasAuthorship W4387600029A5038725561 @default.
• W4387600029 hasAuthorship W4387600029A5044428342 @default.
• W4387600029 hasAuthorship W4387600029A5050973081 @default.
• W4387600029 hasAuthorship W4387600029A5059965188 @default.
• W4387600029 hasAuthorship W4387600029A5065643161 @default.
• W4387600029 hasAuthorship W4387600029A5074572683 @default.
• W4387600029 hasAuthorship W4387600029A5085027597 @default.
• W4387600029 hasAuthorship W4387600029A5092222367 @default.
• W4387600029 hasBestOaLocation W43876000291 @default.
• W4387600029 hasConcept C1491633281 @default.
• W4387600029 hasConcept C2776938444 @default.
• W4387600029 hasConcept C2779787849 @default.
• W4387600029 hasConcept C2908647359 @default.
• W4387600029 hasConcept C2992270614 @default.
• W4387600029 hasConcept C41625074 @default.
• W4387600029 hasConcept C523546767 @default.
• W4387600029 hasConcept C53227056 @default.
• W4387600029 hasConcept C54355233 @default.
• W4387600029 hasConcept C55493867 @default.
• W4387600029 hasConcept C58123911 @default.
• W4387600029 hasConcept C71924100 @default.
• W4387600029 hasConcept C86803240 @default.
• W4387600029 hasConcept C89423630 @default.
• W4387600029 hasConcept C99454951 @default.
• W4387600029 hasConceptScore W4387600029C1491633281 @default.
• W4387600029 hasConceptScore W4387600029C2776938444 @default.
• W4387600029 hasConceptScore W4387600029C2779787849 @default.
• W4387600029 hasConceptScore W4387600029C2908647359 @default.

• next